Has Michael Dent, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,811 in general payments to Michael Dent, MD across 123 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Dent, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Dent, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Dent, MD

MOHS-Micrographic Surgery · Indianapolis, INNPI 1881821585

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $948, 9.7 times the $97 reported in 2019.

$2,811in general payments, 2019–2025

Across 123 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$566
Regeneron Healthcare Solutions, Inc.$297
Pfizer$242
Galderma Laboratories, L.p.$198
Novartis$191
Dermavant Sciences, Inc.$181
plus $1K from 18 others

What the payments were for

Food & beverage$2,811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	28	$566
Regeneron Healthcare Solutions, Inc.	13	$297
Pfizer	12	$242
Galderma Laboratories, L.p.	10	$198
Novartis	6	$191
Dermavant Sciences, Inc.	2	$181
Lilly USA, LLC	9	$162
Amgen	9	$137
Journey Medical Corporation	1	$117
Stemline Therapeutics Inc.	1	$112
Ortho Dermatologics, A Division Of Bausch Health US, LLC	6	$83
Organogenesis Inc.	2	$68
Boehringer Ingelheim	1	$66
LEO Pharma Inc.	4	$63
Johnson & Johnson	4	$61
Sun Pharmaceutical Industries Inc.	3	$56
E.r. Squibb & Sons, L.L.C.	3	$48
Incyte Corporation	2	$40
Sanofi	2	$39
Almirall LLC	1	$26
Genentech USA, Inc.	1	$18
Botanix SB Inc	1	$16
UCB, Inc.	1	$14
Biofrontera Inc.	1	$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Rinvoq$113
NEMLUVIO$108

How this compares

Too few mohs-micrographic surgery providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$724,736

Medicare patients

811

Services billed

2,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluorouracil	65	$5,300
Doxycycline Hyclate	342	$3,369
Triamcinolone Acetonide	180	$1,605
Fluocinolone Acetonide	23	$1,453
Fluocinonide	31	$1,003
Clobetasol Propionate	17	$820
Ketoconazole	47	$638
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet	14	$457
Cephalexin	34	$168
Mupirocin	16	$140
Tramadol Hcl	15	$30
Lorazepam	14	$17

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Indianapolis

Carl HankeIndianapolis$96K
Kelly McCoyIndianapolis$2K
Michael KunzIndianapolis$425
Rachel WardMuncie$9K
Eduardo RiveraMadison$8K
John RandallWest Lafayette$6K
David SurprenantEvansville$5K
Brian WilliamsGreenwood$5K
Perry HooperCarmel$5K
Shayna GordonPlainfield$4K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →